Robert E. Hoffman - 13 Jul 2026 Form 4 Insider Report for Esperion Therapeutics, Inc. (ESPR)

Reporting relationship: Director
Issuer ticker: ESPR
Reported as of: 13 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Jul 2026, 16:06:15 UTC
Prior SEC filing: 23 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Sheldon L. Koenig, by power of attorney

Key filing fact

Robert E. Hoffman filed Form 4 for Esperion Therapeutics, Inc. (ESPR) on 13 Jul 2026.

Key facts

This page summarizes Robert E. Hoffman's Form 4 filing for Esperion Therapeutics, Inc. (ESPR).
3 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 13 Jul 2026, 16:06.

Change

Previous filing in this sequence was filed on 23 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001166288 Primary reporting owner

Hoffman Robert E.

Relationship: Director
Address: C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR
Signature: /s/ Sheldon L. Koenig, by power of attorney
Signature date: 13 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ESPR transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -85,153
Change %: -100%
Price
Shares after: 0
Date: 13 Jul 2026
Ownership: Direct
Footnotes: F1, F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ESPR transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -40,000
Change %: -100%
Price
Shares after: 0
Date: 13 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 40,000
Exercise price: $1.41
Footnotes: F1, F4

ESPR transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -7,040
Change %: -100%
Price
Shares after: 0
Date: 13 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,040
Exercise price: $0.8700
Footnotes: F1, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Robert E. Hoffman is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 4 footnotes

Footnote F1

This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.

Footnote F2

At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the "per share cash consideration"), and (b) one contractual contingent value right per share (each, a "CVR" and, together with the per share cash consideration, the "merger consideration"), representing the right to participate in contingent payments in cash, without interest, upon the achievement of certain milestones, subject to any applicable withholding taxes. From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.

Footnote F3

Includes 79,873 restricted stock units (each, a "RSU"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive, with respect to each share of Common Stock subject to such RSU immediately prior to the effective time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the per share cash consideration, plus (b) one CVR, subject to certain exceptions.

Footnote F4

At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR.

SEC remarks

Exhibit List: Exhibit 24 - Power of Attorney